Antag, a startup backed by Versant and Novo, joins hunt for obesity drug alternatives

Antag Therapeutics, a seven-year-old Danish startup investigating a hotly debated approach to treating obesity, has raised 80 million euros, or about $84 million, to advance its first weight loss drug into clinical testing.